Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + nivolumab
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Doxorubicin + nivolumab is a combination therapy that pairs a cytotoxic anthracycline (doxorubicin) with an immune checkpoint inhibitor (nivolumab). Doxorubicin is capable of inducing immunogenic cell death (ICD), a specific type of tumor cell death that can trigger an adaptive immune response. Nivolumab is a PD-1 inhibitor that blocks the interaction between PD-1 and its ligands, enhancing T-cell function. The combination is hypothesized to create synergy in the ICD circuit, with doxorubicin's cytotoxic effects potentially enhancing the efficacy of nivolumab's immunotherapeutic action.
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on doxorubicin + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + nivolumab.